Ikena Oncology Inc. (IKNA) Announces 6.11M Share Offering at $6.55/sh May 15, 2023 07:45AM
Ikena Oncology Announces $40 Million Underwritten Offering May 15, 2023 07:45AM
Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days Apr 20, 2023 08:00AM
Ikena Oncology Shares Differentiation Profile of IK-930, a Novel Hippo-Pathway Inhibitor, Including Projected Therapeutic Index Advantages and Breadth of Patient Populations at AACR 2023 Annual Meetin Apr 17, 2023 09:00AM
Ikena Oncology Reports Fourth Quarter and Full Year 2022 Financial Results Mar 14, 2023 07:00AM
View Older Stories

Mar 7, 2023 08:10AM Ikena Oncology Inc. (IKNA) Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR
Mar 7, 2023 08:00AM Ikena Oncology Presents Preclinical Data on IK-595, Best-in-Class Next-Generation MEK-RAF Complex Inhibitor, in Plenary Session at AACR Special Conference on RAS Targeting
Mar 6, 2023 08:01AM Ikena Oncology (IKNA) Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma
Mar 6, 2023 08:00AM Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma
Feb 28, 2023 08:00AM Ikena Oncology to Participate in Cowen 43rd Annual Health Care Conference
Dec 19, 2022 04:30PM Ikena Oncology Appoints Owen Hughes as Board Chair
Nov 28, 2022 08:18AM Ikena Oncology Inc. (IKNA) Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update
Nov 28, 2022 08:00AM Ikena Oncology Announces New Program in Next-Generation MEK-RAF Inhibition and Provides Corporate Update
Nov 22, 2022 07:30AM Ikena Oncology to Participate in the Piper Sandler 34th Annual Healthcare Conference
Nov 10, 2022 09:04AM Ikena Oncology Inc. (IKNA) Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma
Nov 10, 2022 09:00AM Ikena Oncology Announces Initial Clinical Data from IK-175 Program in Urothelial Carcinoma
Nov 7, 2022 08:48AM UPDATE -- Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
Nov 7, 2022 08:05AM Ikena Oncology Reports Third Quarter 2022 Financial Results and Provides a Corporate Update
Oct 26, 2022 07:31AM Ikena Oncology Inc. (IKNA) Presents New Preclinical Data
Oct 26, 2022 07:30AM Ikena Oncology Presents Preclinical Data at the 34th EORTC-NCI-AACR Symposium on Novel TEAD Inhibitor, IK-930, Combating Therapeutic Resistance
Oct 18, 2022 07:33AM Ikena Oncology (IKNA) Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway
Oct 18, 2022 07:30AM Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway
Oct 5, 2022 08:05AM Ikena Oncology to Present Initial Phase 1a/b Results from Novel AHR Inhibition Program at the 2022 Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
Sep 6, 2022 07:30AM Ikena Oncology to Participate in September 2022 Investor Conferences
Aug 11, 2022 07:30AM Ikena Oncology Reports Second Quarter 2022 Financial Results and Provides a Corporate Update
Jul 6, 2022 07:00AM Ikena Oncology to Participate in the William Blair Biotech Focus Conference 2022
Jun 22, 2022 07:30AM Ikena Oncology Inc. (IKNA) Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma
Jun 22, 2022 07:00AM Ikena Oncology Receives FDA Fast Track Designation for Novel TEAD Inhibitor IK-930 to Treat Unresectable NF2-Deficient Mesothelioma
May 18, 2022 07:00AM Ikena Oncology to Participate in Spring 2022 Investor Conferences
May 12, 2022 07:00AM Ikena Oncology Reports First Quarter 2022 Financial Results and Provides a Corporate Update
May 2, 2022 07:00AM Ikena Oncology and Vall d’Hebron Institute of Oncology Announce Research & Development Collaboration
May 2, 2022 07:00AM Ikena Oncology and Vall d’Hebron Institute of Oncology Announce Research & Development Collaboration
Apr 28, 2022 07:00AM Ikena Oncology to Present at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
Apr 13, 2022 07:03AM Ikena Oncology Inc. (IKNA) Appoints Jotin Marango as CFO and Head of Corporate Development
Apr 13, 2022 07:00AM Ikena Appoints Jotin Marango, M.D., Ph.D., as Chief Financial Officer and Head of Corporate Development
Mar 17, 2022 07:00AM Ikena Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Corporate Update
Mar 7, 2022 04:30PM Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting
Mar 7, 2022 04:30PM Ikena Oncology to Present Preclinical Findings on IK-930, a Novel TEAD Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting
Mar 1, 2022 07:00AM Ikena Oncology to Participate in Cowen 42nd Annual Health Care Conference
Jan 26, 2022 07:08AM Ikena Oncology Inc. (IKNA) Appoints Richard Wooster to its Board
Jan 26, 2022 07:00AM Ikena Appoints Richard Wooster, Ph.D., to its Board of Directors
Dec 8, 2021 07:03AM Ikena Oncology Inc. (IKNA) Appoints Michelle Zhang as Chief Scientific Officer
Dec 8, 2021 07:00AM Ikena Appoints Michelle Zhang, Ph.D., Industry and Company Veteran, as Chief Scientific Officer
Nov 12, 2021 07:00AM Ikena Oncology Presents Data at SITC 36th Annual Meeting Describing the Indication Selection Methodology, Translational Data, and Trial in Progress for IK-175
Nov 10, 2021 07:00AM Ikena Oncology Reports Third Quarter 2021 Financial Results and Corporate Update
Nov 4, 2021 07:00AM Ikena Oncology to Participate in November 2021 Virtual Investor Conferences
Nov 2, 2021 08:04AM Ikena Oncology Inc. (IKNA) Announces FDA Acceptance of IND Application of Novel TEAD Inhibitor IK-930
Nov 2, 2021 08:00AM Ikena Oncology Announces FDA Acceptance of IND Application of Novel TEAD Inhibitor IK-930
Oct 7, 2021 09:00AM Ikena Oncology Presents Data at AACR-NCI-EORTC Virtual Conference Demonstrating Potential of TEAD Inhibitors in Cancer Treatment
Oct 1, 2021 08:15AM Ikena Oncology (IKNA) to Present Trial-in-Progress Update, Translational Data, and Indication Selection Methodology for Novel AHR Inhibition Program at SITC
Oct 1, 2021 08:15AM Ikena Oncology to Present a Trial-in-Progress Update, Translational Data, and Indication Selection Methodology for Novel AHR Inhibition Program at the 2021 Society for Immunotherapy of Cancer (SITC) 3
Oct 1, 2021 08:15AM Ikena Oncology to Present a Trial-in-Progress Update, Translational Data, and Indication Selection Methodology for Novel AHR Inhibition Program at the 2021 Society for Immunotherapy of Cancer (SITC) 3
Sep 2, 2021 07:00AM Ikena Oncology to Participate in September 2021 Virtual Investor Conferences
Sep 2, 2021 07:00AM Ikena Oncology to Participate in September 2021 Virtual Investor Conferences
Aug 12, 2021 07:00AM Ikena Oncology Reports Second Quarter 2021 Financial Results and Provides Update on Key Programs
View Older Stories